Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma

Archives of Surgery

Volumn 142, Issue 8, 2007, Pages 717-727

  Wiseman, Sam M ^a   Griffith, Obi L ^a   Deen, Shaun ^a   Rajput, Ashish ^a   Masoudi, Hamid ^a   Gilks, Blake ^a   Goldstein, Lynn ^b   Gown, Allen ^a   Jones, Steven J M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PHENOPATH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MESSENGER RNA; PROTEIN P53; PROTEIN RET; RADIOACTIVE IODINE; VASCULOTROPIN;

ANAPLASTIC CARCINOMA; ARTICLE; ASPIRATION BIOPSY; CANCER SURVIVAL; CANCER TISSUE; CELL DIFFERENTIATION; CELL PROLIFERATION; DOWN REGULATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GRAVES DISEASE; HUMAN; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIATION EXPOSURE; SIGNAL TRANSDUCTION; THYROID CARCINOMA;

AGED; AGED, 80 AND OVER; CADHERINS; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 34548088376     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.142.8.717     Document Type: Article

References (46)

1. Fox MS, Klawansky S. Interruption of cell transformation and cancer formation. FASEB J. 2006;20(13):2209-2213.
2. Wiseman SM, Loree TR, Rigual NR, et al. Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck. 2003;25(8):662-670.
3. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447-1463.
4. Shaha AR, Shah JP, Loree TR. Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg. 1997;174(5):474-476.
5. Gilliland FD, Hunt WC, Morris DM, et al. Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer. 1997;79(3):564-573.
6. O'Neill JP, O'Neill B, Condron C, et al. Anaplastic (undifferentiated) thyroid cancer: improved insight and therapeutic strategy into a highly aggressive disease. J Laryngol Otol. 2005;119(8):585-591.
7. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 2006;13(4):453-464.
8. Ain KB. Anaplastic thyroid carcinoma a therapeutic challenge. Semin Surg Oncol. 1999;16(1):64-69.
9. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma: treatment outcome and prognostic factors. Cancer. 2005;103(7):1330-1335.
10. Tennvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 2002;86(12):1848-1853.
11. De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60(4):1137-1143.
12. Ain KB, Egorin MJ, DeSimone PA; Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Thyroid. 2000;10(7):587-594.
13. Wiseman SM, Masoudi H, Niblock P, et al. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol. 2007;14(2):719-729.
14. Parker RL, Huntsman DG, Lesack DW, et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol. 2002;117(5):723-728.
15. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc [Ser B]. 1995;57(1):289-300.
16. Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol. 2003;169(4):1219-1228.
17. Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol. 2002;14(1):86-91.
18. Blagosklonny MV, Giannakakou P, Wojtowicz M, et al. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab. 1998;83(7):2516-2522.
19. Lowe SW. Cancer therapy and p53. Curr Opin Oncol. 1995;7(6):547-553.
20. Lam KY, Lo CY, Chan KW, Wan KY. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann Surg. 2000;231(3):329-338.
21. Yoshida A, Fukazawa M, Ushio H, Aiyoshi Y, Soeda S, Ito K. Study of cell kinetics in anaplastic thyroid carcinoma transplanted to nude mice. J Surg Oncol. 1989;41(1):1-4.
22. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23(28):7212-7220.
23. Kjellman P, Wallin G, Hoog A, Auer G, Larsson C, Zedenius J. MIB-1 index in thyroid tumors: a predictor of the clinical course in papillary thyroid carcinoma. Thyroid. 2003;13(4):371-380.
24. Lee A, LiVolsi VA, Baloch ZW. Expression of DNA topoisomerase IIα in thyroid neoplasia. Mod Pathol. 2000;13(4):396-400.
25. Karayan-Tapon L, Menet E, Guilhot J, Levillain P, Larsen CJ, Kraimps JL. Topoisomerase II alpha and telomerase expression in papillary thyroid carcinomas. Eur J Surg Oncol. 2004;30(1):73-79.
26. Järvinen TA, Liu ET. Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer-more common than anticipated. Cytopathology. 2003;14(6):309-313.
27. Cardoso F, Durbecq V, Larsimont D, et al. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol. 2004;24(1):201-209.
28. Saltman B, Singh B, Hedvat CV, Wreesmann VB, Ghossein R. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. Surgery. 2006;140(6):899-906.
29. Fluge O, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE. Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid. 2006;16(2):161-175.
30. Satake S, Sugawara I, Watanabe M, Takami H. Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines. Cancer Lett. 1997;116(1):33-39.
31. Ordóñez NG, El-Naggar AK, Hickey RC, et al. Anaplastic thyroid carcinoma: immunocytochemical study of 32 cases. Am J Clin Pathol. 1991;96(1):15-24.
32. Van Aken E, De Wever O, Correia da Rocha AS, et al. Defective E-cadherin/ catenin complexes in human cancer. Virchows Arch. 2001;439(6):725-751.
33. Ilyas M. Wnt signalling and the mechanistic basis of tumour development. J Pathol. 2005;205(2):130-144.
34. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J. Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg. 2006;191(5):581-587.
35. Pollina L, Pacini F, Fontanini G, Vignati S, Bevilacqua G, Basolo F. bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Br J Cancer. 1996;73(2):139-143.
36. Pilotti S, Collini P, Rilke F, Cattoretti G, Del Bo R, Pierotti MA. Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol. 1994;172(4):337-342.
37. Kim R, Tanabe K, Uchida Y, Emi M, Toge T. Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma. Int J Mol Med. 2003;11(6):799-804.
38. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer. 2004;100(12):2491-2499.
39. Lin JD, Chao TC. Vascular endothelial growth factor in thyroid cancers. Cancer Biother Radiopharm. 2005;20(6):648-661.
40. Huang SM, Lee JC, Wu TJ, Chow NH. Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J Surg. 2001;25(3):302-306.
41. Vieira JM, Santos SC, Espadinha C, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. Eur J Endocrinol. 2005;153(5):701-709.
42. Dziba JM, Marcinek R, Venkataraman G, Robinson JA, Ain KB. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid. 2002;12(12):1063-1070.
43. Straight AM, Oakley K, Moores R, et al. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. Cancer Chemother Pharmacol. 2006;57(1):7-14.
44. Bauer AJ, Terrell R, Doniparthi NK, et al. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid. 2002;12(11):953-960.
45. Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O'Sullivan B. A comparison of different staging systems predictability of patient outcome: thyroid carcinoma as an example. Cancer. 1997;79(12):2414-2423.
46. Shaha A. Treatment of thyroid cancer based on risk groups. J Surg Oncol. 2006;94(8):683-691.